Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) EV-to-Revenue : 157.39 (As of May. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Shanghai Junshi Biosciences Co's enterprise value is $2,989.97 Mil. Shanghai Junshi Biosciences Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $19.00 Mil. Therefore, Shanghai Junshi Biosciences Co's EV-to-Revenue for today is 157.39.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's EV-to-Revenue or its related term are showing as below:

SHJBF' s EV-to-Revenue Range Over the Past 10 Years
Min: -41.82 Med: 29.18 Max: 612.26
Current: 159.51

During the past 8 years, the highest EV-to-Revenue of Shanghai Junshi Biosciences Co was 612.26. The lowest was -41.82. And the median was 29.18.

SHJBF's EV-to-Revenue is ranked worse than
86.68% of 1036 companies
in the Biotechnology industry
Industry Median: 8.17 vs SHJBF: 159.51

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-29), Shanghai Junshi Biosciences Co's stock price is $1.86. Shanghai Junshi Biosciences Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02. Therefore, Shanghai Junshi Biosciences Co's PS Ratio for today is 97.89.

Shanghai Junshi Biosciences Co EV-to-Revenue Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co EV-to-Revenue Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

23.82

24.25

10.10

26.35

10.45

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial														31.47	14.53	10.45	10.45	54.51

Competitive Comparison of Shanghai Junshi Biosciences Co's EV-to-Revenue

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's EV-to-Revenue falls into.

Shanghai Junshi Biosciences Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Shanghai Junshi Biosciences Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2989.965	/	18.997
	=	157.39

Shanghai Junshi Biosciences Co's current Enterprise Value is $2,989.97 Mil.
Shanghai Junshi Biosciences Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.00 Mil.

Shanghai Junshi Biosciences Co (OTCPK:SHJBF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Shanghai Junshi Biosciences Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.86	/	0.019
	=	97.89

Shanghai Junshi Biosciences Co's share price for today is $1.86.
Shanghai Junshi Biosciences Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.

Shanghai Junshi Biosciences Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

01877:Hong Kong 8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) Headlines

From GuruFocus

Shanghai Junshi's Anti-Covid-19 Drug Hits Phase 3 Clinical Trials

By Alberto Abaterusso • 11-23-2021

Junshi Biosciences, Legend Biotech and Zai Lab Are 3 Top Chinese Biotechs

By Barry Cohen Barry Cohen • 11-19-2020

Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab

By PRNewswire PRNewswire • 02-03-2021